NCT01378117View on ClinicalTrials.gov

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Type 2 Diabetes MellitusHospitalizationHyperglycemia
Interventions
DRUG

Sitagliptin

Sitagliptin 50-100mg po once daily

DRUG

glargine

glargine once daily

DRUG

lispro

lispro before meals

Trial Locations (2)

30303

Grady Memorial Hospital, Atlanta

30324

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Emory University

OTHER

NCT01378117 - Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter